




### CONTENT

|  | Page | Category                     |  |  |
|--|------|------------------------------|--|--|
|  | 2    | Antibody Workflow            |  |  |
|  | 3    | Timeline & Options           |  |  |
|  | 4    | Milestones & Guarantee       |  |  |
|  | 5    | Classic Immunization         |  |  |
|  | 6    | Speedy Immunization          |  |  |
|  | 7    | IgG Proteases                |  |  |
|  | 8    | Fab Production               |  |  |
|  | 9    | <b>Custom Peptides</b>       |  |  |
|  | 10   | <b>Peptide Modifications</b> |  |  |
|  | 11   | Automated IHC                |  |  |
|  | 12   | Tissue Microarray            |  |  |
|  |      |                              |  |  |




Abcepta is a leading manufacturer of primary antibodies, with a core team of experts working together for more than 20 years in bioreagent development and service.

Deep and practical understanding of the production and validation process for antibodies, peptides, and recombinant proteins.


World-class, credentialed facility and highly trained staff who rigorously test our deliverables inprocess and post-production.

Stringent internal monitoring with abundant client communication to assure that we earn the trust of those who choose to work with us.



# Antibody Production Workflow

Abcepta scientists have developed more than 25,000 monoclonal and polyclonal antibodies for commercial, academic, and governmental labs worldwide. Through our Custom Antibody Production Service, clients access proprietary resources and technical knowledge optimized from extensive experience in antigen design, peptide conjugation, immunization, and purification.






### Timeline & Options

Abcepta offers comprehensive custom antibody services. Capabilities include peptide antigen design (including site-specific modified versions such as phosphopeptides), synthesis, serum collection and hybridoma fusions, and purification. Customizations include cleavage, lyophilization, custom vialing and validation by Western Blot, IHC, IF and IP






conjugation is also available on request.

### Milestones & Guarantee

- Free Consultation and Experimental Design
- Strict Confidentiality
- Flexible Customization
- Optimized antigen preparation, immunization, screening, and purification
- Rigorous Quality Control
- Short Turn Around Time
- Competitive Price





### Classic Immunization: ~10 weeks

|  | Subject              | New Zealand Rabbits for polyclonal antibody generation.  |
|--|----------------------|--|
|  | Adjuvants            | Use of conventional and/or proprietary adjuvants (e.g Antibody Express).   |
|  | Immunogen<br>Options | Synthesize one peptide (12-22aa, purity>85%). Conjugate the peptide to carrier protein (KLH, BSA or OVA). 50-100 µg immunogen is used per immunization.  |
|  |                      | Customer provides antigen protein. Protein may be checked by OD, SDS-PAGE or MS.   |
|  |                      | If antigen protein is IgG and requires fragmentation, additional information may be requested and discussed with customer.   |
|  |                      | Customer may provide expression vector to express and purify the antigen protein.  |
|  |                      | Customer may provide gene and protein information, to clone the gene and construct the expression vector (for fusion protein) and express and purify the antigen protein.                                    |
|  | Schedule             |  |
|  | Week 0               | Bleed 10 ml (yields 2-3 ml pre-immune serum). Immunize with 200 µg/rabbit antigen in adjuvant.   |
|  | Week 1               | Prepare materials for second immunization.   |
|  | Week 2               | Immunize with 100 μg/rabbit antigen in adjuvant.   |
|  | Week 3               | Prepare materials for third immunization.  |
|  | Week 4               | Immunize with 100 μg/rabbit antigen in adjuvant.   |
|  | Week 5               | Test bleed 10-20 ml/rabbit. Specific antibody screening via ELISA performed against antigen. Immunize with 100 μg/rabbit antigen in PBS.   |
|  | Week 6               | 1 <sup>st</sup> Production bleed 20-30 ml if test positive. Immunize with 100 μg/rabbit antigen in PBS.  |
|  | Week 7               | 2 <sup>nd</sup> Production bleed 20-30 ml. Immunize with 100 μg/rabbit antigen in PBS. ELISA test again if previous tests were negative. If negative, consult with client regarding continuation of project. |
|  | Week 8               | 3 <sup>rd</sup> Production bleed 20-30 ml. Immunize with 100 μg/rabbit antigen in PBS.   |
|  | Week 9               | 4 <sup>th</sup> Production bleed 20-30 ml. Immunize with 100 μg/rabbit antigen in PBS.   |
|  | Week 10              | Terminating bleed 30-50 ml/rabbit.   |
|  |                      | The antibody is purified by an Antigen Specific Affinity purification. Average yield of purified Ig fraction is 100-150 mgs.   |

# Speedy Immunization: ~5 weeks

\* Reactogenicity analysis may exclude eligibility. Inquire for details


| Antibody Express™                             | An adjuvant with unique characteristics to accelerate timelines                              |
|---|--|
|   |  |
| Quicker immune response                       | Requires just two immunizations generating immune response within 3 weeks.                   |
|   |  |
| High Titer                                    | Antibodies with ELISA titers 1:10,000~1:10,000,000 elicited by week 5.                       |
|   |  |
| Antigen-sparing effects                       | Permits lower dosing of antigen (typically 5~20 ug per injection)                            |
|   |  |
| No destruction of native antigen conformation | Facilitates generation of monoclonal antibodies against conformational epitopes.             |
|   |  |
| Non-protein composition                       | Eliminates contamination from epitope competition compared to adjuvants containing proteins. |
|   |  |
| No emulsification required                    | Formulated as a ready-to-use consistent solution freshly prepared prior to immunization.     |
|   |  |
| No foot-pad or intra-spleen immunization      | Antibody Express™ adjuvant safely applied through intra-muscular injection.                  |
|   |  |



### Abcepta IgG Proteases


Abcepta employs four unique enzymes for preparation of antigen-specific formats of Fab fragments. These proteolytic enzymes digest antibodies from several species and subclasses into selectable subunits.

### FabriCut Enzyme Panel



### Fab Production

Enzymatic digestion of IgG results in F(ab')2 and Fc/2 fragments that can be reduced to antibody subunits.



Abcepta FabriCut proteases are a group of proteolytic enzymes that digest antibodies from several species and subclasses into subunits. Ideal for development of antigens for Anti-drug antibody (ADA) assays.

Trastuzumab digested by immobilized FabriCut. Pure Fab fragments were obtained in a high yield from all three subclasses into subunits.

| Enzyme                                 | FabriCut-1   | FabriCut-2            | FabriCut-3    | FabriCut-4  | FabriCut-1.1  |
|--|--|-----------------------|---------------|---|---|
| IgG species<br>and subclasses          | Human IgG1-4,<br>mouse IgG2a<br>and IgG3, some<br>classes of rat,<br>monkey, rabbit<br>and sheep | Human lgG1            | Human lgG1    | Human IgG,<br>mouse, rat, goat,<br>sheep and rabbit | Human IgG1-4,<br>Mouse IgG2a<br>and IgG3, some<br>classes of<br>monkey, rabbit<br>and sheep |
| Digestion site<br>(human IgG1)         | LLG / GPS  | DKT / HTC             | CDK / THT     | THT / CPP   | LLG / GPS   |
| Above / below<br>hinge (human<br>IgG1) | Below  | Above                 | Above         | Above   | Below   |
| Reaction requirements                  | Physiological buffers  | Physiological buffers | 2 mM cysteine | Reducing conditions                                 | Physiological buffers   |
| Reaction time                          | 30 min   | O/N                   | 1 h           | 1 h   | 2 h   |
| рН                                     | 5.5 - 8  | 6 - 8                 | 8             | 6.5 - 8   | 5.5 - 8   |



### Custom Peptides

Abcepta peptide chemists have synthesized >20,000 peptides, leveraging > 20 years expertise to deliver to our clients custom peptide solutions meeting stringent quality control standards for identity and purity. In addition to rapid routine synthesis, Abcepta applies the latest technical innovations to execute challenging projects, such as hydrophobic peptides, long peptides (>100 amino acids), and peptides with structural complexity.

#### **KEY FEATURES**


| Peptide length*      | 2-140 amino acids                |  |
|----------------------|----------------------------------|--|
| Modifications        | Over 400 modifications available |  |
| Scale                | 1 mg–1 g                         |  |
| Purity               | Crude-98%                        |  |
| QC                   | MALDI MS and HPLC                |  |
| <b>Delivery time</b> | 2–3 weeks                        |  |


<sup>\*</sup> Please inquire about shorter or longer peptide lengths

#### **Purity vs Applications** Blocking and competition assays Enzyme-substrate studies (quantitative) Western blotting studies Receptor-ligand interaction studies Production of antibodies (non-quantitative) (quantitative) for immunizations Enzyme-substrate studies ELISA and RIA (quantitative) Screening purposes Determination of the titer (non-quantitative) in vivo / in vitro studies of antibodies in standard ELISA Phosphorylation studies High precision quantitative Affinity purification proteomics (see Quant-Peptides p.10) ≥ 90-95% ≥ 80% ≥70% crude

## Peptide Modifications

Peptide modification feasibility is dependent on the peptide sequence, properties and desired location. Hence, our technical team will review each request case by case. Modifications can be of the following types: N-terminal; C-terminal, Structural; Conjugation; and Unnatural Amino Acid (UAADs). Unnatural Amino Acid (UAADs) can be exploited to enhance the stability or functionality of a therapeutic target, and can be site specifically incorporated into your synthetic custom peptides. Examples include post-translational modifications such as the carboxylation of glutamate (forming the UAA-gamma-carboxy glutamate), and hydroxylation of proline (forming the UAA-hydroxyproline).








### Automated IHC

#### Polymer-Based Immunohistochemistry (IHC)

To overcome limitations associated with avidinbiotin systems, Abcepta offers a detection system with higher sensitivity and specificity, employing a polymer-based IHC technique.

Up to 70 enzyme (Ez) molecules and 10 primary antibodies (Abs) are conjugated to a polymeric backbone. This detection construct permits the entire IHC staining procedure to be accomplished in a single rapid step.



Exceed pathologists' TAT expectations for complete case delivery with Abcepta's automated IHC staining system. A single high-throughput system completes 5 cases (30 slides) in 2.5 hours; multiple instruments further accelerate data output.

|          | HEMATOPATHOLOGY PANELS |           |           |         |  |
|----------|------------------------|-----------|-----------|---------|--|
|          | Panel A                | Panel B   | Panel C   | Panel D |  |
| Ave. TAT | 2:33:06                | 2:36:07   | 2:28:39   | 2:28:39 |  |
|          | BCL2                   | BCL2      | BCL2      | BCL2    |  |
|          | BCL6                   | BCL6      | CD3       | BCL6    |  |
|          | CD3                    | CD3       | CD5       | CD3     |  |
|          | CD5                    | CD5       | CD10      | CD10    |  |
|          | CD10                   | CD10      | CD20      | CD20    |  |
|          | CD20                   | CD20      | CD21      | CD45    |  |
|          | CD21                   | CD21      | CD23      | Ki67    |  |
|          | CD23                   | CD23      | Cyclin D1 | TdT     |  |
|          | Cyclin D1              | Cyclin D1 | Kappa     |         |  |
|          | Kappa                  | Ki67      | Lambda    |         |  |
|          | Lambda                 |           |           |         |  |

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Hodgkin's Lymphomas. Version 4.2014.

### Tissue Microarray

#### **Abcepta Tissue Microarray Analysis (TMA)**

Cylindrical cores are obtained from up to 1,000 individual formalin-fixed, paraffin-embedded blocks. These are transferred to a recipient TMS block, which is sectioned up to 300 times. All resulting TMA slides present the same tissues in the same coordinate positions. The individual slides can be used for a variety of analyses, saving labor and reagent costs while maintaining uniformity of assay. Typically a minimum of three 0.6 mm cores are used for each case.

#### Overview of multiplex IHC using Abcepta TMA

After preprocessing, hematoxylin staining for identification of nuclei is followed by up to 10 IHC iterations, including antigen retrieval, antibody incubation, whole slide scanning, and antibody stripping. IHC markers are customizable to client specifications.


#### **Advantages of Abcepta TMA**


IHC is performed on a large number of patient samples in an efficient and cost-effective manner.

Hundreds of cores from several hundred patients can be included in a single glass slide for simultaneous assay.

Significantly more tissue is conserved compared to serial sectioning of tissue blocks.

Abcepta TMAs apply to all tissue types, including decalcified bone and core biopsies.







#### Contact

John Mountzouris, PhD
Chief Scientific Officer
j.m@abcepta.com

#### Abcepta Inc.

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Phone +1-858-875-1900
www.abcepta.com

